Compare KTTA & ATCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | ATCX |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | Brazil |
| Employees | 5 | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 20.0M |
| IPO Year | N/A | N/A |
| Metric | KTTA | ATCX |
|---|---|---|
| Price | $0.51 | $2.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $13.75 |
| AVG Volume (30 Days) | ★ 312.7K | 9.1K |
| Earning Date | 05-14-2026 | 03-16-2023 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $827,667.00 |
| Revenue Next Year | N/A | $166.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $2.57 |
| 52 Week High | $2.06 | $14.01 |
| Indicator | KTTA | ATCX |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 30.54 |
| Support Level | $0.42 | N/A |
| Resistance Level | $0.52 | $3.17 |
| Average True Range (ATR) | 0.04 | 0.19 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.94 | 0.00 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.